Insiders who reported open-market trades in the last 12 months at the companies Mark A. Goldsmith files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Margaret A. Horn - $25.81M in RVMD purchases and sales in the last 12 months
Mark A. Goldsmith is a corporate insider, tracked as President and Chief Executive Officer, Director of Revolution Medicines, Inc. (RVMD). InsiderAlpha holds 21 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Mark A. Goldsmith submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Mark A. Goldsmith been buying or selling stock?
Recorded transactions: 0 open-market purchases and 55 open-market sales ($64.51M) across all tracked filings.
Mark A. Goldsmith is President and Chief Executive Officer, Director of Revolution Medicines, Inc. (RVMD). 21 SEC Form 4 filings on record going back to 2024, most recently on 18 September 2026. Most recent open-market trade: sold $2.75M of RVMD on 18 September 2026. Lifetime open-market sales: $64.51M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Mark A. Goldsmith.
InsiderAlpha's records for Mark A. Goldsmith go back to 2024: 21 primary Form 4 filings, an average of 7.0 per year. 91 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
